TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
TCL Archive NCI’s Otis Brawley Named Professor At Emory, Associate Director, Cancer Control, At Winship. April 20, 2001
TCL Archive In Brief: NCI Gets $867 Million From Conferees; Grants To Be Funded At 41-42% Including Some Holdovers July 29, 1977
